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Refractory cytopenia of childhood (RCC) is the most common subtype of myelodysplastic syndrome in chil-
dren, and the clinical course of RCC is heterogeneous. A certain proportion of RCC patients need allogeneic
hematopoietic stem cell transplantation (HSCT); however, data on HSCT outcomes are not abundant, and the
optimal intensity of a preparative conditioning regimen remains uncertain. In this study, we evaluated the
outcomes of HSCT in 24 patients with RCC. Eleven patients received myeloablative conditioning (MAC)
consisting of high-dose cytarabine, cyclophosphamide, and either total body irradiation (TBI) or busulfan.
Nine patients (38%) received a reduced-intensity conditioning (RIC) regimen; of these, 7 received low-dose
TBI and cyclophosphamide (200 mg/kg) with or without antithymocyte globulin or ﬂudarabine, and 2 pa-
tients received low-dose TBI, ﬂudarabine, and melphalan (140 mg/m2). The remaining 4 patients had disease
progression before HSCT and received the MAC regimen. With a median follow-up of 91 months (range, 6 to
263), the probability of overall survival at 5 years was 81.1% (95% CI, 57.0 to 92.5). The 5-year overall survival
for the 15 patients who received MAC was 73.3% (95% CI, 43.6 to 89.1), and all 9 patients with RIC are alive
without any events. Further study is needed to evaluate the efﬁcacy of RIC for children with RCC with an
expectation for reduction of late effects such as growth retardation and infertility.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Refractory cytopenia of childhood (RCC) is the most
common subtype of myelodysplastic syndrome (MDS) in
children, characterized by persistent cytopenia with <5%
blasts in the bone marrow (BM), <2% blasts in the peripheral
blood, and dysplastic changes in 2 or 3 lineages or exceeding
10% in 1 single cell line [1-4]. Some patients with RCC
without cytogenetic abnormalities may experience a long,
stable clinical course of the disease. For patients without a
transfusion requirement, severe neutropenia, or infections,
careful observation (watch and wait) is the reasonable
treatment strategy. In contrast, hematopoietic stem cell
transplantation (HSCT) is the treatment of choice for patients
with monosomy 7 or complex karyotypes because of the risk
of progression to advanced MDS [3,4]. HSCT can also be
recommended for patients with other karyotypes if a suit-
able donor is available [2,4]. Practically, some RCC patients
need HSCT for the reason of transfusion dependency or
severe neutropenia and/or infection irrespective of the
presence of cytogenetic abnormalities.
Reported disease-free survival rates after HSCT in patients
with MDS range between 30% and 75% in previous reports,
most of which included patients with various subtypes of
MDS, ranging from RCC to advanced MDS, juveniledgments on page 568.
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14.12.003myelomonocytic leukemia, and therapy-related MDS [5-10].
However, limited data are available on the outcome of HSCT
focusing on patients with RCC [3,11]. Therefore, little is
known regarding treatment-related factors associated with
transplant outcome, such as the optimal intensity of condi-
tioning regimen for patients with RCC. In 2007, Strahm et al.
[11] reported that a reduced-intensity conditioning (RIC)
regimen consisting of ﬂudarabine (Flu), thiotepa, and
antithymocyte globulin achieved favorable outcomes of
HSCT in children with hypocellular refractory cytopenia
without chromosomal abnormality. In this study, we report
the outcomes of HSCT in 24 pediatric patients with RCC after
conditioning regimens of myeloablative conditioning (MAC)
with high-dose cytarabine, cyclophosphamide (CY), and total
body irradiation (TBI) or busulfan (BU) and RIC with low-
dose TBI and CY or melphalan (Mel).METHODS
Patients
Twenty-four patients with RCC aged < 19 years at diagnosis received
HSCT at the Department of Pediatrics, National Kyushu Cancer Center be-
tween April 1991 and May 2014. Fifteen patients were diagnosed with re-
fractory anemia or refractory cytopenia with multilineage dysplasia based
on the French-American-British classiﬁcation or World Health Organization
1999 criteria [12,13]. All 24 patients were compatible with the classiﬁcation
of RCC according to the World Health Organization 2008 criteria [4,14].
BM biopsy to evaluate marrow cellularity was performed in 19 patients
(79%). Patients who had received previous HSCT, those with inherited BM
failure disorder, such as Fanconi anemia or dyskeratosis congenita, or those
with treatment-related MDS were excluded. The most frequent reasons for
recommendation of HSCT were transfusion dependency in 14 patients, fol-
lowed by monosomy 7 in 4, and disease progression to advanced MDS in 3.
All patients or their parents provided written informed consent for
HSCT. This retrospective study and patient data use was approved by the
institutional review board of the National Kyushu Cancer Center. Patient
characteristics are shown in Table 1.
Table 1
Patient Characteristics
Number of patients 24
Median age at HSCT, yr (range) 10 (3-21)
Median time from diagnosis to HSCT, mo (range) 13.5 (3-95)
Sex
Male 14
Female 10
Cytogenetics at diagnosis
Normal 14
Monosomy 7 5
Trisomy 8 2
Structural complex 1
Other abnormalities 1
Unknown 1
Disease progression before HSCT
Yes 4
No 20
Year of HSCT
1991-2000 8
2001-2014 16
Donor
MSD-BM 8
MUD-BM 12
UCB 4
Conditioning regimen
BU/CA/CY 8
TBI/CA/CY 5
TBI/Others 2
RIC 9
GVHD prophylaxis
CsA based 11
TaC based 13
MSD indicates matched sibling donor; MUD, matched unrelated donor;
UCB, unrelated cord blood; CA, cytarabine; CsA, cyclosporine; Tac,
tacrolimus.
Figure 1. Outcomes of HSCT in 24 patients with RCC. After the ﬁrst HSCT,
treatment-related death was observed in 1 patient who had disease pro-
gression before HSCT. No patient who received RIC relapsed, and 1 of 11 pa-
tients who received MAC without disease progression relapsed after HSCT.
One of 4 patients with disease progression before HSCT is alive in remission.
J. Inagaki et al. / Biol Blood Marrow Transplant 21 (2015) 559e574566The study included 14male and 10 female patients, with amedian age of
10 years (range, 3 to 21) at the time of HSCT. Before HSCT, 18 patients had
neutropenia (absolute neutrophil count < 1.0  109/L), and 12 patients had
ANC < .5  109/L. The number of transfusions for RBCs and/or platelets
before HSCTwas> 10 times in 20 patients and>20 times in 17 patients. Four
patients experienced disease progression to advanced MDS (refractory
anemia with excess blast in 3 patients and acute myeloid leukemia in 1
patient) before HSCT at a median of 11 months (range, 3 to 17) from diag-
nosis. Cytogenetic analysis at diagnosis was available in 23 patients,
including normal karyotype (n ¼ 14), monosomy 7 with or without addi-
tional aberrations (n ¼ 5), structurally complex karyotype (deﬁned as more
than 3 chromosomal aberrations in the presence of at least 1 structural
aberration, n ¼ 1), or other abnormalities such as trisomy 8 (n ¼ 3). Sixteen
patients received immunosuppressive therapy, including steroid therapy in
4 patients, cyclosporine A in 2 patients, and antithymocyte globulin in
combination with cyclosporine A in 10 patients as the initial treatment for
RCC. Two patients with disease progression received acute myeloid leuke-
miaeoriented chemotherapy.Transplantation Procedures
Until 2006, 11 patients received the MAC regimen consisting of high-
dose cytarabine (12 g/m2), CY (120 mg/kg), and either TBI (12 Gy) or BU
(Figure 1). Another 4 patients with disease progression before HSCT received
the MAC regimen, which was determined at the treating physician’s
discretion. Since 2007, the RIC regimen has been applied to patients with
RCC, and a total of 9 patients (38%) received RIC. Six patients with hypo-
cellular marrow without monosomy 7 or a structural complex karyotype
received low-dose TBI (3 Gy) and CY (200 mg/kg) with antithymocyte
globulin or Flu. Two patients with normocellular marrow received low-dose
TBI (3 or 4 Gy), Flu (125 mg/m2), and Mel (140 mg/m2). One patient with
hypocellular marrowwho underwent HSCT in 2004 received RIC with TBI (3
Gy) and CY (200 mg/kg), because he was initially diagnosed with aplastic
anemia. Transplantation characteristics of these 9 patients who received the
RIC regimen are shown in Table 2.
Cyclosporine A with or without short-term methotrexate was used as
prophylaxis for acute graft-versus-host disease (GVHD) in 11 patients;
tacrolimus was used with or without short-term methotrexate in 13 pa-
tients. Stem cell sources were BM for 20 patients and cord blood for 4
patients. Eight patients received BM transplantation from an HLA-matchedsibling donor, 12 patients received BM transplantation from an HLA-
matched unrelated donor, and 4 patients received unrelated cord blood
stem cell transplantation.
Deﬁnitions and Statistical Analysis
Engraftment was deﬁned as the ﬁrst day when the absolute neutrophil
count reached .5  109/L for 3 consecutive days. Both the platelets and re-
ticulocytes were considered to be recovered when they reached counts
>20  109/L and >1%, respectively, without transfusion support. Graft fail-
ure was deﬁned as a lack of engraftment irrespective of donor chimerism. A
chimerism analysis was performed using BM samples when engraftment
was observed. Fluorescence in situ hybridization with sex chromosomes for
sex-mismatched HSCT and short tandem repeat PCR for sex-matched HSCT
was carried out. Acute and chronic GVHD were diagnosed and classiﬁed
according to previously reported criteria [15,16]. Overall survival (OS) was
calculated as the time from HSCT to death or last follow-up. Probability of
survival was estimated by the Kaplan-Meier methodwith the corresponding
95% conﬁdence intervals (CI). Univariate analysis of OS was performed using
the log-rank test. All statistical analyses were performed using SPSS version
19 (SPSS Co., Tokyo, Japan).
RESULTS
Engraftment, GVHD, and Complications
Twenty-three of 24 patients (96%) were engrafted on a
median of day 17 (range, 11 to 49). Graft failure occurred in 1
patient who had disease progression to refractory anemia
with excess blast before unrelated cord blood stem cell
transplantation. Thereafter, he had autologous recovery and
relapsed. Platelet and reticulocyte recovery was achieved on
a median of day 27 (range, 17 to 75) in 21 assessable patients
and day 25 (range, 17 to 41) in 22 assessable patients,
respectively. The data on 16 patients were available for
chimerism analysis, and all 16 patients showed complete
donor chimerism when engraftment was observed. All 9
patients who received the RIC regimen engrafted with
complete donor chimerism.
Acute GVHD of grades II to III occurred in 12 of 23
assessable patients including 8 of 14 patients (57%) withMAC
and 4 of 9 (44%) with RIC. No grade IV acute GVHD occurred.
Chronic GVHD occurred in 5 of 21 assessable patients. In 9
patients with RIC, only 1 (11%) developed mild chronic GVHD
limited to skin, whereas 4 of 12 patients (33%) with MAC
developed chronic GVHD, including 3 with the severe type.
Within 100 days after HSCT, viral infections were the most
frequent complication. In patients with MAC, 9 patients
(60%) developed cytomegalovirus infection, including 8 pa-
tients with cytomegalovirus reactivation in the blood and 1
with interstitial pneumonia. In patients with RIC,
Table 2
Characteristics and Outcomes of RCC Patients with RIC
Patient
No.
Age
(yr)/
Sex
Cellularity Cytogenetics Treatment
before
HSCT
Diagnosis
to HSCT
(mo)
Donor Conditioning Regimen
(Dose of TBI or chemotherapy)**
GVHD
Prophylaxis
Acute
GVHD
Chronic
GVHD
Complication
within 100 days
Prognosis (follow-upmo)
1 5/M Hypocellular Unknown PSL 28 MSD-BM TBI (3)/CY (200) CsA 0 No Alive in remission (122)
2 14/M Hypocellular Normal ATG, CsA, mPSL 40 MUD-
BM
TBI (3)/CY (200)/ATG (10) Tac/sMTX II Mild CMV
antigenemia
Alive in remission (87)
3 10/F Hypocellular Normal ATG, CsA, mPSL 10 MUD-
BM
TBI (3)/CY (200)/ATG (10) Tac/sMTX 0 No CMV
antigenemia
HC (BK virus)
Alive in remission (48)
4 14/M Hypocellular Trisomy 8 ATG, CsA, mPSL 14 MUD-
BM
TBI (3)/CY (200)/ATG (10) Tac/sMTX 0 No Alive in remission (37)
5 4/F Hypocellular Normal CsA 22 MUD-
BM
TBI (3)/CY (200)/ATG (10) Tac/sMTX I No Alive in remission (39)
6 11/F Hypocellular Normal CsA 15 MUD-
BM
TBI (3)/CY (200)/ATG (5) Tac/sMTX II No Alive in remission (11)
7 5/F Hypocellular Normal ATG, CsA, mPSL 13 MUD-
BM
TBI (3)/CY (200)/Flu (120)/
ATG (2.5)*
Tac/sMTX III No CMV
antigenemia
HC (BK virus)
Alive in remission (13)
8 3/F Normocellular Structural
complex
No treatment 3 MSD-BM TBI (3)/Flu (125)/Mel (140) CsA I No Alive in remission (6)
9 13/M Normocellular Normal ATG, CsA, mPSL 20 UCB TBI (4)/Flu (125)/Mel (140) Tac/sMTX/MMF III No CMV entelitis Alive in remission (12)
PSL indicates prednisone; ATG, antithymocyte globulin; sMTX, short-term methotrexate; CMV, cytomegalovirus; mPSL, methylprednisolone; MUD, matched unrelated donor; MMF, mycophenolate mofetil.
All patients received rabbit ATG (Zetbulin [Fresenius, Bad Homburg, Germany] for early 4 patients and Thymoglobulin [Genzyme, Lyon, France] for 2 patients).
* This patient was intolerant of ATG and received Flu instead of ATG.
** TBI, Gy; CY, mg/kg; ATG, mg/kg; Flu, mg/m2; Mel, mg/m2.
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J. Inagaki et al. / Biol Blood Marrow Transplant 21 (2015) 559e574568cytomegalovirus infection occurred in 4 patients (44%;
reactivation in the blood in 3 patients and enteritis in 1). All
were treated successfully with ganciclovir or foscarnet so-
dium hydrate. Six patients (4 patients with MAC and 2 with
RIC) developed hemorrhagic cystitis due to BK virus infection
in 3 patients, adenovirus in 1, and unknown cause in the
remaining 2 patients. They were treated with hydration and
diuretics and thereafter improved.
Treatment-Related Death, Relapse, and Survival
Outcomes of HSCT of all patients are shown in Figure 1.
Treatment-related death was observed in 1 patient who had
disease progression and underwent HSCT with MAC, result-
ing in death from interstitial pneumonia 1 month after HSCT.
No patient who received RIC relapsed, whereas 3 of 15 pa-
tients who received MAC relapsed at 1, 2, and 20 months
after HSCT. One of the 3 relapsed patients had monosomy 7,
and the remaining 2 relapsed patients had disease progres-
sion before HSCT. All 3 patients underwent a second HSCT,
resulting in treatment-related death (interstitial pneumonia,
sinusoidal obstructive syndrome, and bronchiolitis obliter-
ans organizing pneumonia).
With a median follow-up of 91 months (range, 6 to 263),
20 patients survived, and the probability of OS at 5 years was
81.1% (95% CI, 57.0 to 92.5). The 5-year OS for the 15 patients
who received MAC was 73.3% (95% CI, 43.6 to 89.1), and all 9
patients who received RIC are alive in remission with a me-
dian follow-up of 37 months (range, 6 to 122) without
relapse, treatment-related death, and chronic GVHD for
which systemic treatment is required (Table 2).
DISCUSSION
In the recent report of the European Working Groups of
MDS, of 115 hypocellular RCC children without a high-risk
karyotype who were given immunosuppressive therapy as
frontline treatment, 40 patients ultimately underwent HSCT
because of failure in immunosuppressive therapy [17]. The
report from the Japanese Society of Pediatric Hematology/
Oncology shows that 10 of 25 patients who received
immunosuppressive therapy and 6 of 27 patients who were
treated with a watch and wait strategy were thereafter
transplanted [18]. The results of these 2 reports indicate that
a certain proportion of RCC patients need HSCTafter ﬁrst-line
treatment, and the OS rate after HSCT was favorable (80% at 4
years in the former and 66% at 5 years in the latter report)
with an extremely low relapse rate. In the current study, the
probability of OS at 5 years for all 24 patients was 81%, which
compares favorably with these reports and a previous report
[3]. Although only a small number of patients were included,
the present results suggest that both the MAC and RIC regi-
mens used in our institution are feasible for patients with
RCC without increasing the risk of treatment-related mor-
tality, which remains the most common cause of death in
HSCT for children with MDS [5-7]. As previously described,
the prognoses of patients with disease progression before
HSCT were dismal [3]. Early referral for HSCT might be
preferred for patients with unfavorable cytogenetic abnor-
malities or transfusion dependency.
For patients with advanced MDS, the MAC regimen con-
sisting of BU, CY, and Mel offered about 60% of event-free
survival in the EWOG-MDS report [7]. In contrast, the
optimal conditioning regimen for HSCT in patients with RCC
is uncertain. At our institution, pediatric patients with MDS
have been treated with MAC with high-dose cytarabine, CY,
and either TBI (12 to 13.2 Gy) or BU irrespective ofmorphological classiﬁcation or BM cellularity. A RIC regimen,
which is the same as regimens for aplastic anemia, was
applied to patients with hypocellular RCC, because of a
suggested pathological overlap between aplastic anemia and
hypoplastic RCC [19,20]. As shown in Table 2, all 7 patients
who received the RIC regimen consisting of TBI (3 Gy) and CY
(200 mg/kg) had hypocellular marrow without unfavorable
cytogenetics such as monosomy 7 or a structural complex
karyotype. In support of the report by Strahm et al. [11], the
current results suggest that HSCT using RIC could be prom-
ising in children with hypocellular RCC, with an expected
reduction in late effects such as growth retardation and
infertility.
The feasibility of RIC for RCC patients with normocellular
or hypercellular marrow and/or with unfavorable cytoge-
netics remains to be evaluated. In our study, HSCT using RIC
consisting of low-dose TBI, Flu (125 mg/m2), and Mel (140
mg/m2) was performed for 2 patients with normocellular
RCC, whose follow-up period is too short. Further large-sized
studies with a long-term follow-up will better evaluate the
efﬁcacy of RIC for children with RCC.
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The pathophysiology of acute graft-versus-host disease (GVHD) remains poorly understood in humans.
Although T cell subsets have been identiﬁed to play a major role in disease initiation in rodents, clinical data
on the effect of these different subsets are scarce and conﬂicting. To address this question, immunopheno-
typing analyses were performed on the graft in 210 patients. The onset of acute GVHD was retrospectively
correlated with these subpopulations. In an adjusted analysis, only the absolute count of CD45lo/CD62Llo
CD8þ T cells (effector memory T cells) was signiﬁcantly associated with the onset of grade 2 to 4 acute GVHD.
Thus, in contrast to experimental data, we found that the number of effector memory but not of naïve T cells
was associated with the onset of GVHD. These results should be kept in mind while clinical trials, which aim
to deplete naïve T cells, are underway in several institutions.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD), the leading
cause of transplantation-relatedmortality [1,2], still occurs in
40% to 70% of transplantations [3,4]. Donor T cells are major
effectors of both graft-versus-host disease (GVHD) and
graft-versus-leukemia effects [5,6]. During the last decade.
T cells subsets have been investigated to better understand
the chronology of and to predict onset of aGVHD. They aredivided into 4 main subsets: naïve, central memory, effector
memory, and terminally differentiated T cells. Naïve and
central memory T cells strongly expressed CD62L. Naïve and
terminally differentiated T cells expressed CD45RA, whereas
other memory T cells do not. Naïve T cells after activation in
lymphoid organs have been implicated in the genesis of
GVHD in experimental models [7,8]. Conversely, alloreactive
effector memory T cells are immediate effectors [9-11]. In
humans, in vitro studies demonstrated an increased capacity
to induce alloreactivity in naïve CD4 T cells [12,13]. A
prospective and a retrospective study in patients tend to
conﬁrm this hypothesis, showing that naïve CD4 T cells
represent a signiﬁcant biomarker of onset aGVHD [14,15].
Nevertheless, these studies included a small number of
patients. As graft engineering now allows efﬁciently
removing the naïve T cell subset [16], with the aim of
